$RVVTF (copy) DD by FRESS - FLASH: Record 108,487 people

$RVVTF (copy) DD by FRESS - FLASH: Record 108,487 people hospitalized...
https://pbs.twimg.com/media/EpE6qJYVgAAPo8b?f...=4096x4096

Doctors treating some COVID patients at home as Alabama hospitals run low on beds..
https://www.al.com/news/2020/12/doctors-treat...-beds.html


Warp Speed Leader Rues Political Pressure... It Won't End Covid Anytime Soon..


Revive Therapeutics Signs MOU with Attwill Medical Solutions for manufacturing of Bucillamine in COVID-19



Science has been validated Bucillamine in the treatment of CV-19
https://www.biorxiv.org/content/10.1101/2020....1.full.pdf

Coronavirus Update 114: COVID 19 Death Rate Drops; NAC (N acetylcysteine) Data (Bucillamine 16x more potent than NAC)
https://www.youtube.com/watch?v=eQO1PB8-xtg

Bucillamine to treat mild-moderate CV-19 cases thats 80% of all cases. this will help millions of people and keep hospital visits down. A drug with very low side effects.

FDA Phase 3 Detailed Description:
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 2:1 to the selected bucillamine dose or placebo The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 10 centers in the United States will conduct this study.
Bucillamine late stage phase 3 trial
ClinicalTrials.gov Identifier: NCT04504734
https://clinicaltrials.gov/ct2/show/NCT04504734

Scientific Rationale for the Investigation of Bucillamine to Treat Infectious Diseases, including COVID-19

Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficacy when not delivered early.1 This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication.2 Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that abrogate the potential for influenza to cause severe disease.3,4,5 Restoration of glutathione, the major intracellular thiol antioxidant, is a critical functional activity of NAC.6 Reactive oxygen species (ROS) generation during influenza virus infection aggravate destructive inflammation and programmed death of epithelial cells.7 Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms.4,7 NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients.5 While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability.

Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.8 Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues8 and is highly cell permeable for efficient delivery into cells.8,9 Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19.


Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Phase 3 CV-19 drugs OTC companies
CYDY 1.8 Billion market cap
RLFTF 1 Billion market cap
RVVTF 90 million late stage Phase 3 low side effects ready to manufacture at scale partnership with Attwill medical solutions
$RVVTF

---

Looks like therapeutics are needed more than ever most people obviously not planning on getting the CV-19 Vaccine.

https://www.worldvaccinepoll.com

THE OFFICIAL THOUGHTS OF COVID-19 POLL.

7 QUESTIONS TO GET THE UNCENSORED OPINION OF THE WORLD


Take the poll yourself.

7 questions.

1. Should vaccines be mandatory? 94.5% said NO

2. Are you getting the Covid-19 vaccine? 91% said NO

3. Was government reaction to Covid-19 worst than the virus? 90% said Yes

4. Do you support lockdowns or military involvement? 92.5% said NO

5. Should mask be mandatory? 90% said NO

6. Do you trust the world health organization? 93% said NO

7. Was Covid-19 politicized by the mainstream media? 94% said YES


$RVVTF